AMR: IMI’s Enable project reaches endpoints
The IMI project was recently granted a one-year extension to promote further progression of ongoing programmes, while keeping within the original budget of about €100m. ENABLE was formed in 2014 to accelerate the development of new antibiotics for the treatment of difficult-to-treat Gram-negative infections. The project has so far identified five antibacterial leads.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.